Lifeway Foods Delivers Record Q2 2025 Net Sales, Extends Kefir Category Leadership, and Estimates Over 20% Q3 Net Sales Growth to Date
Kefir market leader posts
Company posts double-digit diluted EPS gains and strong gross margin expansion year-over-year
Momentum accelerates into Q3 with highest weekly sales ever recorded in July and unaudited estimate of
"This was another quarter that reinforces Lifeway's position as the undisputed leader in the kefir category," said
Smolyansky continued, "Beyond topline growth, we expanded gross margin by 160 basis points year-over-year and more than 460 basis points sequentially, translating into double-digit net income and diluted EPS growth year-over-year. We are executing with discipline while capturing powerful consumer tailwinds – from the continued wellness boom to the surge in GLP-1 medication use – as more people seek nutrient-dense, protein-rich, probiotic foods that support digestion, satiety, and natural GLP-1 hormone production."
Recognized Industry Leadership
In July, Lifeway was named Processor of the Year by
Capitalizing on Growth Trends
In addition to its flagship kefir and Farmer Cheese, Lifeway's Probiotic Smoothies with Collagen – the first in the category – are resonating strongly with consumers. Collagen, a rapidly growing
Third Quarter Momentum
Momentum has carried into the second half of the year. In July, Lifeway recorded the highest single week of gross sales in Company history, surpassing
Second Quarter 2025 Highlights
-
Net Sales :$53.9 million , highest in Company history, up 9.7% year-over-year and approximately 18% on a comparable basis, adjusted for a customer relationship the Company strategically exited in the third quarter of 2024, and a distributor shifting from Lifeway delivered to customer pick-up in late 2024, resulting in lower net sales and lower freight expense. - Gross Profit Margin: 28.6%, up from 27.0% last year
- SG&A: 17.6% of net sales, reflecting continued investment in marketing and distribution
- Net Income:
$4.2 million , or$0.28 per basic and diluted common share, compared to$3.8 million , or$0.26 per basic and$0.25 per diluted share in the prior year
Outlook
The Company reiterated its long-term target of $45–$50 million in Adjusted EBITDA1 for FY 2027 and expressed confidence in delivering the strongest annual sales in Company history in 2025.
"We are just getting started," Smolyansky concluded. "With record sales, expanding margins, category-leading innovation, and a production platform ready to scale, Lifeway is positioned for sustained, profitable growth. The best is yet to come."
- Adjusted EBITDA is a non-GAAP financial measure. Adjusted EBITDA is defined as Operating Income, as reported, plus Depreciation and Amortization, plus Stock-Based Compensation.
Conference Call and Webcast
A webcast with Lifeway's President and Chief Executive Officer discussing these results with additional comments and details is available through the "Investor Relations" section of the Company's website at https://lifewaykefir.com/webinars-reports/.
About
Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the drivers of demand for Lifeway's products, consumer trends, the anticipated effects of scheduled upgrades at the Waukesha plant, expected operating efficiencies and expectations regarding future operating and financial performance. These statements use words, and variations of words, such as "will," "continue," "future," "increase," "believe," "outlook," "expect," and "predict." You are cautioned not to rely on these forward-looking statements. These forward-looking statements are made as of the date of this press release, are based on current expectations of future events and thus are inherently subject to a number of risks and uncertainties, many of which involve factors or circumstances beyond Lifeway's control. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from Lifeway's expectations and projections. These risks, uncertainties, and other factors include: price competition; the decisions of customers or consumers; the actions of competitors; changes in the pricing of commodities; the effects of government regulation; possible delays in the introduction of new products; customer acceptance of products and services; and uncertainty regarding proposals or other actions taken by shareholders related to the unsolicited proposal made by Danone North America PBC ("Danone") to acquire all of the shares of Lifeway stock that Danone does not already own. A further list and description of these risks, uncertainties, and other factors can be found in Lifeway's Annual Report on Form 10-K for the fiscal year ended December 31, 2024. Copies of these filings are available online at https://www.sec.gov, http://lifewaykefir.com/investor-relations/, or on request from Lifeway. Lifeway expressly disclaims any obligation to update any forward-looking statements (including, without limitation, to reflect changed assumptions, the occurrence of anticipated or unanticipated events or new information), except as required by law.
Non-GAAP Financial Measures
This press release refers to Adjusted EBITDA, which is a financial measure that has not been prepared in accordance with
We are unable to reconcile our target fiscal year 2027 Adjusted EBITDA to projected net income, the most directly comparable projected GAAP financial measure, because certain information necessary to calculate such measures on a GAAP basis is unavailable or dependent on the timing of future events outside of our control. Due to this uncertainty, the Company cannot reconcile target fiscal year 2027 Adjusted EBITDA to the nearest GAAP financial measure without unreasonable effort.
Derek Miller
Vice President of Communications,
Email: derekm@lifeway.net
Email: dtarman@perceptualadvisors.com
General inquiries:
Phone: 847-967-1010
Email: info@lifeway.net
|
||||||||
|
||||||||
|
|
|
|
|
|
|
||
|
|
(Unaudited) |
|
|
2024 |
|
||
Current assets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
21,220 |
|
|
$ |
16,728 |
|
Accounts receivable, net of allowance for credit losses and discounts & allowances of |
|
|
16,065 |
|
|
|
15,424 |
|
Inventories, net |
|
|
10,224 |
|
|
|
8,678 |
|
Prepaid expenses and other current assets |
|
|
1,822 |
|
|
|
2,144 |
|
Refundable income taxes |
|
|
– |
|
|
|
631 |
|
Total current assets |
|
|
49,331 |
|
|
|
43,605 |
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net |
|
|
30,731 |
|
|
|
26,862 |
|
Operating lease right-of-use asset |
|
|
278 |
|
|
|
118 |
|
|
|
|
11,704 |
|
|
|
11,704 |
|
Intangible assets, net |
|
|
6,088 |
|
|
|
6,358 |
|
Other assets |
|
|
135 |
|
|
|
1,900 |
|
Total assets |
|
$ |
98,267 |
|
|
$ |
90,547 |
|
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
11,880 |
|
|
$ |
10,401 |
|
Accrued expenses |
|
|
4,409 |
|
|
|
5,103 |
|
Total current liabilities |
|
|
16,289 |
|
|
|
15,504 |
|
Operating lease liabilities |
|
|
220 |
|
|
|
70 |
|
Deferred income taxes, net |
|
|
3,062 |
|
|
|
3,062 |
|
Total liabilities |
|
|
19,571 |
|
|
|
18,636 |
|
|
|
|
|
|
|
|
|
|
Stockholders' equity |
|
|
|
|
|
|
|
|
Preferred stock, no par value; 2,500 shares authorized; none issued |
|
|
– |
|
|
|
– |
|
Common stock, no par value; 40,000 shares authorized; 17,274 shares issued; 15,221 |
|
|
6,509 |
|
|
|
6,509 |
|
|
|
|
(13,268) |
|
|
|
(14,052) |
|
Paid-in capital |
|
|
2,844 |
|
|
|
4,632 |
|
Retained earnings |
|
|
82,611 |
|
|
|
74,822 |
|
Total stockholders' equity |
|
|
78,696 |
|
|
|
71,911 |
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders' equity |
|
$ |
98,267 |
|
|
$ |
90,547 |
|
|
||||||||||||||||
|
||||||||||||||||
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net sales |
|
$ |
53,901 |
|
|
$ |
49,157 |
|
|
$ |
99,992 |
|
|
$ |
93,791 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of goods sold |
|
|
37,669 |
|
|
|
35,181 |
|
|
|
71,923 |
|
|
|
67,619 |
|
Depreciation expense |
|
|
832 |
|
|
|
701 |
|
|
|
1,634 |
|
|
|
1,362 |
|
Total cost of goods sold |
|
|
38,501 |
|
|
|
35,882 |
|
|
|
73,557 |
|
|
|
68,981 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
|
15,400 |
|
|
|
13,275 |
|
|
|
26,435 |
|
|
|
24,810 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling expense |
|
|
4,718 |
|
|
|
3,577 |
|
|
|
9,416 |
|
|
|
7,277 |
|
General and administrative expense |
|
|
4,752 |
|
|
|
4,177 |
|
|
|
9,380 |
|
|
|
8,313 |
|
Amortization expense |
|
|
135 |
|
|
|
135 |
|
|
|
270 |
|
|
|
270 |
|
Total operating expenses |
|
|
9,605 |
|
|
|
7,889 |
|
|
|
19,066 |
|
|
|
15,860 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from operations |
|
|
5,795 |
|
|
|
5,386 |
|
|
|
7,369 |
|
|
|
8,950 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
(21) |
|
|
|
(47) |
|
|
|
(35) |
|
|
|
(98) |
|
Fair Value Loss on investments |
|
|
– |
|
|
|
– |
|
|
|
(20) |
|
|
|
– |
|
Gain on sale of investments |
|
|
55 |
|
|
|
– |
|
|
|
3,407 |
|
|
|
– |
|
Other income (expense), net |
|
|
82 |
|
|
|
20 |
|
|
|
156 |
|
|
|
15 |
|
Total other income (expense) |
|
|
116 |
|
|
|
(27) |
|
|
|
3,508 |
|
|
|
(83) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before provision for income taxes |
|
|
5,911 |
|
|
|
5,359 |
|
|
|
10,877 |
|
|
|
8,867 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision for income taxes |
|
|
1,662 |
|
|
|
1,576 |
|
|
|
3,088 |
|
|
|
2,658 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
4,249 |
|
|
$ |
3,783 |
|
|
$ |
7,789 |
|
|
$ |
6,209 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings per common share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
0.28 |
|
|
$ |
0.26 |
|
|
$ |
0.51 |
|
|
$ |
0.42 |
|
Diluted |
|
$ |
0.28 |
|
|
$ |
0.25 |
|
|
$ |
0.51 |
|
|
$ |
0.41 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
15,206 |
|
|
|
14,727 |
|
|
|
15,170 |
|
|
|
14,709 |
|
Diluted |
|
|
15,390 |
|
|
|
15,197 |
|
|
|
15,359 |
|
|
|
15,176 |
|
|
||||||||
|
||||||||
|
|
Six months ended |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
Net income |
|
$ |
7,789 |
|
|
$ |
6,209 |
|
Adjustments to reconcile net income to operating cash flow: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
1,904 |
|
|
|
1,632 |
|
Stock-based compensation |
|
|
927 |
|
|
|
1,296 |
|
Non-cash interest expense |
|
|
9 |
|
|
|
17 |
|
Gain on sale of equipment |
|
|
(115) |
|
|
|
– |
|
Gain on sale of investments |
|
|
(3,407) |
|
|
|
– |
|
Fair value loss on investment |
|
|
20 |
|
|
|
– |
|
(Increase) decrease in operating assets: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
(640) |
|
|
|
(651) |
|
Inventories |
|
|
(1,546) |
|
|
|
650 |
|
Prepaid expenses and other current assets |
|
|
322 |
|
|
|
531 |
|
Refundable income taxes |
|
|
631 |
|
|
|
(180) |
|
Increase (decrease) in operating liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
|
500 |
|
|
|
(574) |
|
Accrued expenses |
|
|
(2,632) |
|
|
|
(366) |
|
Accrued income taxes |
|
|
– |
|
|
|
(474) |
|
Net cash provided by operating activities |
|
|
3,762 |
|
|
|
8,090 |
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
(4,526) |
|
|
|
(3,905) |
|
Proceeds from sale of equipment |
|
|
115 |
|
|
|
– |
|
Proceeds from sale of investments |
|
|
5,206 |
|
|
|
– |
|
Net cash provided by (used in) investing activities |
|
|
795 |
|
|
|
(3,905) |
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
Repayment of note payable |
|
|
– |
|
|
|
(2,750) |
|
Payment of deferred financing costs |
|
|
(65) |
|
|
|
– |
|
Net cash used in financing activities |
|
|
(65) |
|
|
|
(2,750) |
|
|
|
|
|
|
|
|
|
|
Net increase in cash and cash equivalents |
|
|
4,492 |
|
|
|
1,435 |
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at the beginning of the period |
|
|
16,728 |
|
|
|
13,198 |
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at the end of the period |
|
$ |
21,220 |
|
|
$ |
14,633 |
|
|
|
|
|
|
|
|
|
|
Supplemental cash flow information: |
|
|
|
|
|
|
|
|
Cash paid for income taxes, net of (refunds) |
|
$ |
2,457 |
|
|
$ |
3,312 |
|
Cash paid for interest |
|
$ |
26 |
|
|
$ |
89 |
|
|
|
|
|
|
|
|
|
|
Non-cash investing activities |
|
|
|
|
|
|
|
|
Accrued purchase of property and equipment |
|
$ |
1,083 |
|
|
$ |
106 |
|
Right-of-use assets obtained in exchange for lease obligations |
|
$ |
196 |
|
|
$ |
– |
|
View original content to download multimedia:https://www.prnewswire.com/news-releases/lifeway-foods-delivers-record-q2-2025-net-sales-extends-kefir-category-leadership-and-estimates-over-20-q3-net-sales-growth-to-date-302527755.html
SOURCE